Lesson plan

4C-I

4C-I, also known as iodo-Ariadne, 4C-DOI, or DOI-B, as well as 4-iodo-2,5-dimethoxy-α-ethylphenethylamine, is a serotonin 5-HT 2 receptor agonist of the phenethylamine, phenylisobutylamine, and 4C families related to Ariadne (4C-D). It is a close analogue of the psychedelic drugs 2C-I and DOI, with 2C-I having no substitution at the α carbon, DOI having an α-methyl group, and 4C-I having an α-ethyl group. In his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin described testing 4C-I at doses of up to 4 mg orally, but observed no effects and did not assess higher doses. The drug is a potent agonist of the serotonin 5-HT 2A receptor. It shows similar efficacy as an agonist of this receptor as Ariadne, but has 12- to 16-fold higher activational potency in comparison. Like Ariadne, 4C-I produces an attenuated head-twitch response relative to the psychedelic drug DOPR, with a similar maximal response as Ariadne. The chemical synthesis of 4C-I has been described. 4C-I first described in the scientific literature by Alexander Shulgin and colleagues in 1977. Subsequently, it was described in greater detail by Michael Cunningham and colleagues in 2023.

Back to article

Article summary

4C-I, also known as iodo-Ariadne, 4C-DOI, or DOI-B, as well as 4-iodo-2,5-dimethoxy-α-ethylphenethylamine, is a serotonin 5-HT 2 receptor agonist of the phenethylamine, phenylisobutylamine, and 4C families related to Ariadne (4C-D). It is a close analogue of the psychedelic drugs 2C-I and DOI, with 2C-I having no substitution at the α carbon, DOI having an α-methyl group, and 4C-I having an α-ethyl group. In his 1991 book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin described testing 4C-I at doses of up to 4 mg orally, but observed no effects and did not assess higher doses. The drug is a potent agonist of the serotonin 5-HT 2A receptor. It shows similar efficacy as an agonist of this receptor as Ariadne, but has 12- to 16-fold higher activational potency in comparison. Like Ariadne, 4C-I produces an attenuated head-twitch response relative to the psychedelic drug DOPR, with a similar maximal response as Ariadne. The chemical synthesis of 4C-I has been described. 4C-I first described in the scientific literature by Alexander Shulgin and colleagues in 1977. Subsequently, it was described in greater detail by Michael Cunningham and colleagues in 2023.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.